NASDAQ OMX

CellAegis Announces First Distribution Agreement for autoRIC® in Europe

Dela

TORONTO, April 24, 2018 (GLOBE NEWSWIRE) -- CellAegis Devices Inc. ("CellAegis") a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective solutions for acute and chronic cardiovascular conditions, today announced that it has entered into a definitive agreement with Cardiologic Ltd., for the marketing and distribution of its autoRIC® device (http://cellaegis.com/products/) in the United Kingdom ("UK") and Ireland. 

The autoRIC® device automatically delivers remote ischemic conditioning ("RIC") to provide a non-invasive, cardio-protective therapy shown to reduce heart damage during heart attacks and certain cardiovascular procedures.  The technology is CE Marked, and Health Canada approved, and is currently limited to investigational use in the United States.

"This marks the first distribution agreement for the autoRIC® device outside of Canada and is a significant step forward for our international commercialization strategy," said Rocky Ganske, Chief Executive Officer of CellAegis. "Cardiologic's strong track record of success launching innovative medical devices and novel technologies in the UK and Ireland, combined with its focus on improving both the treatment and the standard of care for cardiology and cardiac surgery patients, makes them an ideal partner for CellAegis as we work to introduce autoRIC® to clinicians in Europe."

"We are delighted to have CellAegis' autoRIC® device as a key product in our portfolio," said Martyn Dixon, Managing Director of Cardiologic. "This distribution agreement for the UK and Ireland will give us the opportunity to enhance our offering in interventional cardiology addressing the very significant costs caused by ischemic and reperfusion injuries. These are exciting times."

ERIC-PPCI and CONDI-II Clinical Trials

Two major clinical trials (ERIC-PPCI and CONDI-II) designed to further evaluate the safety and efficacy of the autoRIC® device are nearing completion in the UK, Denmark, Spain and Serbia with top-line results anticipated in the second half of 2019. These trials are randomized studies enrolling 5,400 ST-elevation myocardial infarction ("STEMI") patients.  The primary efficacy endpoints of the trials are mortality and hospitalization for heart failure at one-year post primary percutaneous coronary intervention ("pPCI"). These trials are expected to support expanded adoption of CellAegis' proprietary technology in Europe.

About RIC

RIC is a noninvasive therapeutic that uses four cycles of limb occlusion and reperfusion to protect the myocardium against ischemia-reperfusion injury. RIC is a promising adjunctive treatment to PCI in the prevention of ischemic-reperfusion injury and minimization of postinfarction heart failure in STEMI patients. Previous proof-of-concept clinical studies using RIC before or during a major ischemic event have demonstrated improvements in surrogate markers of ischemia, such as increased myocardial salvage and reduced infarct size, in a variety of clinical scenarios including acute STEMI, elective PCI, and coronary artery bypass grafting surgery. Furthermore, in patients with STEMI, RIC before PCI has been shown to reduce the incidence of contrast-induced acute kidney injury and has prevented acute kidney injury in patients undergoing cardiopulmonary bypass-assisted cardiac surgery.

The autoRIC® device is designed to provide remote ischemic conditioning to adult patients over 18 years of age undergoing cardiothoracic surgery, interventional cardiothoracic procedures or patients with evolving myocardial infarction. The technology is intended for use in hospital and ambulance settings as directed by healthcare professionals.

About CellAegis Devices

CellAegis Devices, headquartered in Toronto, Canada, is the world leader in automated remote ischemic conditioning. The company has patented and developed the non-invasive autoRIC® device, which delivers remote RIC to patients with acute and chronic cardiovascular conditions. The autoRIC® device has CE Mark and Health Canada approvals for treatment during heart attacks, cardiothoracic or surgical procedures. Investigator sponsored clinical research studies for chronic conditions such as heart failure and stroke are also underway. The autoRIC® device was developed from the clinical work of clinicians and researchers at Toronto's world-renowned Hospital for Sick Children.

About Cardiologic Ltd.

Cardiologic Ltd., headquartered in North Yorkshire, UK, specializes in the development, marketing and distribution of innovative medical devices and novel technologies to improve both the treatment and the standard of care for cardiology and cardiac surgery patients. The company works closely with cardiologists, cardiac surgeons, technicians and nursing staff to provide a highly competent technical support and professional assistance in both the catheter laboratory and the cardiac operating theatre. Cardiologic's extensive network allows it to quickly introduce innovative therapies into the UK market, and work closely with suppliers to develop strategies for rapid and sustained success.

Forward-Looking Statements

This press release may contain forward-looking statements identified by words such as "expects", "anticipates", "will" and similar expressions, which reflect CellAegis' current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. The forward-looking statements are made as of the date of this press release and CellAegis does not undertake and is not obligated to publicly update such forward looking statements to reflect new information, subsequent events or otherwise, except as required by law.

Contact:
Rocky Ganske
Chief Executive Officer
rganske@cellaegisdevices.com
www.cellaegis.com/products
www.cardiologic.co.uk/autoric.html




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CellAegis Devices Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Sciaky Receives Order for Multiple Electron Beam Additive Manufacturing (EBAM®) Systems to Strengthen America's Defense and Power Generation Programs21.5.2018 09:00Pressmeddelande

CHICAGO, May 21, 2018 (GLOBE NEWSWIRE) -- Sciaky, Inc., a subsidiary of Phillips Service Industries, Inc. (PSI) and leading provider of metal additive manufacturing (AM) solutions, announced today that it has received an order for multiple Electron Beam Additive Manufacturing (EBAM®) systems to bolster the nation's defense and power generation programs. Details of the project are confidential. "Sciaky has a long history of providing innovative solutions to America's military and power generation initiatives," said Scott Phillips, President and CEO of Sciaky, Inc. "Our EBAM process is the only industrial-grade metal 3D printing technology to produce large-scale parts for land, sea, air, and space applications." As the most widely scalable metal additive manufacturing solution in the industry (in terms of work envelope), Sciaky's EBAM systems can produce parts ranging from 8 inches (203 mm) to 19 feet (5.79 meters) in length. EBAM is also the fastest deposition process in the metal addit

Clean Motion skalar upp med mikrofabriker runt om i världen med hjälp av digital masterfabrik från Siemens.21.5.2018 08:11Pressmeddelande

Elfordonstillverkaren Clean Motion, tillverkarare av den elektriska trehjulingen Zbee, har en global expansionsstrategi som bygger på distribuerad lokal tillverkning i många, mindre fabriker nära slutkunden. För att lyckas med en sådan expansion är det viktigt att säkerställa en digitalt definierad produkt och tillverkningsprocess tillsammans med en centralt kontrollerad leverantörskedja. Clean Motion tar nu nästa steg i sin digitaliseringsprocess tillsammans med Siemens, där digitala tvillingar möjliggör en fullt digitaliserad virtuell produkt, tillverkningsprocess och fabrik. Clean Motion har inlett ett samarbete med Siemens och Virtual Engineering för att realisera sin digitaliseringsstrategi. Som en del av den strategin kommer en digital masterfabrik att byggas i Siemens PLM mjukvara. Fabriken kommer sedan möjliggöra anpassningar för införandet av nya varianter samt optimering av produktionsflöden. Clean Motion kommer kunna bygga upp ett stort antal oberoende fysiska fabriker och s

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressmeddelande

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

BIMobject AB: BIMobject publicerar årsredovisning för 201718.5.2018 17:25Pressmeddelande

BIMobject, som digitaliserar byggbranschen bland annat via molnbaserade plattformar, har idag publicerat årsredovisningen för 2017 på bolagets hemsida. "Det är med stolthet vi offentliggör årsredovisningen för året 2017 - ett år som för oss inte kan beskrivas annat än som 'explosivt'. Det är fantastiskt roligt att se hur vi fortsätter att effektivisera branscher som äntligen börjar se nyttan och digitaliseringens fulla potential. Att vi sedan har fyra starka trender som ger oss vind i seglet gör framtiden ännu mer lockande. Nu är vi i ett spännande 2018 där vi bland annat ser fram emot att passera milstolpen 1 miljon användare", säger Stefan Larsson, VD på BIMobject. Årsredovisningen finns tillgänglig för nedladdning på: http://info.bimobject.com/bimobject_data/documents/Documents/2017/bimobject-%C3%A5rsredovisning-2017.pdf För mer information, vänligen kontakta: Stefan Hansson - CFO Tel: +46 40 - 685 29 00 E-mail: press@bimobject.com ______________________________________________ Denn

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressmeddelande

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

Mandalay Resources Corporation går ut med resultaten från årsstämman samt registreringen av ESTMA-rapporten och utnämningen av styrelseledamot17.5.2018 22:00Pressmeddelande

TORONTO den 17 maj 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) har nöjet att meddela resultatet från årsstämman ("årsstämman") som hölls i dag i Toronto, Ontario. Alla resolutioner som presenterades vid årsstämman godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 79,15 % av de totalt utestående aktierna vid tidsfristen för fullmakter den 14 maj 2018. Val av styrelseledamöter Som meddelat den 14 maj 2018, har Mark Sander avgått som Bolagets President och Chief Executive Officer och drog också tillbaka sin kandidatur för återval till styrelsen. Som resultat fastställdes antalet styrelseledamöter till fem medlemmar och samtliga av de fem nominerade som fanns i bolagsledningens informationsutskick från den 13 april 2018 ("informationsutskicket"), undantaget Mark Sander, valdes om till Bolagets styrelse. Abraham Jonker förblir ledande oberoende styrelseledamot och Bradford Mills fortsätter som styrelseordförande.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum